drugset / Trial / NCT04887935
Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
Phase 1
Terminated
5 enrolled
Washington University School of Medicine
Swim Across America · collabThe Foundation for Barnes-Jewish Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot study of the tolerability and safety of neoadjuvant dapagliflozin for patients with unfavorable intermediate, high-risk, or very high-risk prostatic adenocarcinoma prior to radical prostatectomy. The primary hypothesis is that four weeks of daily dapagliflozin prior to surgery is well-tolerated and safe to use in this patient population. The investigators also hypothesize that dapagliflozin will be efficacious in resulting in tumor shrinkage on pre-operative imaging and will result in tumor necrosis at prostatectomy.
Timeline
- Start
- 2024-06-04
- Primary completion
- 2025-11-26
- Completion
- 2025-11-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | Oral |